Program
ALKS 7290
A development code. Also written as “ALKS 7290 Dose”.
Its studies are mostly in Attention Deficit Disorder with Hyperactivity · Depressive Disorder, Major, led by Alkermes.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alkermes | 22 open or running | phase 2since Aug 5, 2026 | Aug 5, 2026 | Jul 2027phase 2 · NCT07755410 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 5, 2026First study: phase 2 study in Attention Deficit Disorder with HyperactivityFirst studyNCT07755410 · 312 planned · United States
- Oct 22, 2026Phase 2 study in Depressive Disorder, MajorNCT07901179 · 180 planned · United States
Ahead
- Jul 2027Primary completion: phase 2 study in Attention Deficit Disorder with HyperactivityNCT07755410
- Jan 2028Primary completion: phase 2 study in Depressive Disorder, MajorNCT07901179
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07901179Depressive Disorder, Major · United States | 2 | Recruiting | Jan 2028 | 180 |
| NCT07755410Attention Deficit Disorder with Hyperactivity · United States | 2 | Recruiting | Jul 2027 | 312 |
How it is read
Names in the registry
- “ALKS 7290”, 1 entry
- “ALKS 7290 Dose”, 1 entry
Codes read as this program: ALKS7290.
Conditions, from the studies’ own filings
- Attention Deficit Disorder with Hyperactivity, 1 study
- Depressive Disorder, Major, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.